© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Progress in the treatment of superficial fungal infections saw a key moment in Japan during the late 1980s, when medicinal chemists introduced liranaftate. At this time, options for managing athlete’s foot and related skin mycoses needed both broader spectrum and optimized topical absorption. Liranaftate grew from these gaps, shaped by research teams looking for a solution not only stronger than basic azoles or older allylamines, but also distinct in molecular flexibility. Its development reflects a classic synergy between curiosity and public health: investing decades into antifungal research, blending discoveries in organic synthesis with patient feedback. Japanese pharmaceutical companies ran extensive trials, feeding data back into molecular modifications and eventually, patents led to world markets curious about this naphthate-based treatment.
Liranaftate appears as a promising topical agent intended for fungal skin diseases such as athlete's foot, ringworm, and jock itch. Unlike systemics, liranaftate is best known in creams or ointments, applied directly to the skin. Its active component, a thiocarbamate derivative, distinguishes it from imidazoles by blocking enzymes required for fungal cell wall biosynthesis. Marketed under brand names including Zefa, Liranafin, and Liranoft, it serves consumers in Japan, China, South Korea, and parts of Southeast Asia. Once spread on an affected area, liranaftate forms a thin barrier, allowing deep penetration while leaving minimal residue, important for both user comfort and consistent dosing. Product inserts and pharmaceutical texts stress its low rate of observable side effects, typically restricted to brief skin irritation or itching.
On a bench or in a laboratory catalog, liranaftate shows up as a pale yellowish solid. Chemists record its molecular formula as C18H25NOS, with a weight near 303.47 g/mol. Its structure features a robust naphthyl core attached to a flexible alkyl-thiocarbamate chain, rendering it sparingly soluble in water but easily dissolved by organic solvents like ethanol, acetone, or ether. Melting point measurements typically hover around 47° to 51°C. Under normal conditions, this stability translates to long shelf life, provided moisture is kept at bay. Remarkably, it resists rapid degradation under heat and ultraviolet exposure, an advantage for both manufacturing and packaging.
Over-the-counter liranaftate products stick to concentrations between 1% and 2%, embedded in hydrocarbon or water-based creams. Product labels, built out of guidance from health ministries, require bold listing of active percentage, excipient content, expiry, batch number, and manufacturing origin. Regulations insist on warnings in case of unexpected hypersensitivity and instruct strict application to externally infected surfaces only, not mucous membranes. Each package insert lays out the expected protocol: twice-daily application, continued for up to four weeks depending on severity. Regulatory audits periodically inspect these labels for compliance regarding claims and precautionary language.
Liranaftate’s industrial synthesis typically starts from two pillars of chemical supply: a substituted naphthol and a relevant isothiocyanate. Workers combine these reactants in an anhydrous solvent, often under nitrogen, assisted by a mild base. This ensures a high-yield nucleophilic substitution, connecting the naphthyl ring to the sulfur-based alkyl chain. Intermediate purification with solvent extraction or crystallization is crucial to clear out remnants of isocyanates or naphthols. Final steps involve drying the product under vacuum and milling it down for accurate blending in ointment bases or creams. Synthetic routes have been tweaked over the years to minimize waste and maximize yield; small improvements in catalyst purity and reaction temperature shave costs across the industry.
Research on liranaftate explores routes for oxidation, esterification, and side-chain elongation, all aimed at developing analogues with broader activity or improved skin permeability. The core naphthyl structure, while stable, allows for substitutions at peripheral carbons: some teams add fluorine or chlorine to test for persistent antifungal effects. Other studies adjust the thiocarbamate side group, changing alkyl length or introducing aryl substituents. Each chemical tweak brings new questions about skin absorption, metabolic breakdown, and dermal retention, so modifications often find themselves back in preclinical stages. Liranaftate’s backbone stays fairly robust compared to more reactive allylamines or imidazole derivatives, which helps ensure low off-target toxicity.
As with many drugs, liranaftate finds itself under multiple aliases across borders and catalogs. Professionals recognize synonyms such as Liranafta, Zefa, and Liranafin. Chemical abstract texts call out its IUPAC designation, N-methyl-N-(naphthalen-2-ylmethyl)thioformamide, while regulatory filings in Japan and Korea refer to ‘ラリナフタート’ or ‘리라나프타트’. Each brand and generic name reflects the same thiocarbamate structure, with packaging colors and form factors varying between markets. Catalogs from Sigma-Aldrich, Tokyo Chemical Industry, and local distributors use these synonyms interchangeably when filling custom orders for research or analytical testing.
Manufacturers and hospital pharmacies lean on a well-documented safety profile for liranaftate. Safety data sheets highlight its low acute toxicity, supported by controlled animal studies and decades of clinical prescribing. Users with broken or severely eczematous skin are urged to avoid direct application, as reports sometimes link this to mild hives or dermatitis. Production adheres to GMP and ISO protocols, which dictate minimum thresholds for solvent residues and microbial contamination. Packaging must block out light and humidity, using metal tubes or lined plastic to extend shelf life. Workers handling concentrated forms follow glove and eyewear guidelines, given that dust generation can irritate membranes if spilled.
Everyday cases of athlete's foot, ringworm, and jock itch count on liranaftate’s speed and direct antifungal punch. Sports medicine clinics and primary care offices suggest it for localized infections that don’t call for oral tablets. In Japan and South Korea, pharmacies rely on it as a first-choice topical, especially for patients intolerant of older agents or azoles. Hospital formularies list liranaftate as safe for both children and adults, barring only infants and individuals with known severe allergies. Treatment protocols recommend keeping the skin clean and dry, with adherence a key part of lowering recurrence. Occasionally, practitioners blend liranaftate with mild cortisones to reduce itch and swelling during the early days of therapy.
Laboratories worldwide explore both the mechanism of liranaftate’s fungicidal action and the molecular docking at squalene epoxidase, a target more commonly blocked by terbinafine. Japanese academic institutions and pharma collaborated for years in optimizing permeability, which allowed for lower dosing with sustained subcutaneous levels. Researchers screen new analogues hoping for activity against rarer dermatophytes and yeasts. Clinical trials periodically survey large outpatient populations for long-term resistance rates and rare allergic reactions. Some reports in international dermatology journals point out that liranaftate’s combination with antiseptics or herbal extracts creates new avenues for resisting emergent antifungal resistance, an issue rising in heavily populated cities with high humidity.
Toxicology studies of liranaftate most often point to a strong margin of safety across mammals. Repeated dose animal models show no teratogenic or mutagenic effect, nor evidence for systemic toxicity at dermal therapeutic ranges. Oral administration in rodents produces only mild transient symptoms at doses well above what a human would experience with normal use. Studies in rabbit eyes and rat skin, both considered more sensitive than human equivalents, yield no signs of irreversible tissue damage. Clinical pharmacovigilance remains ongoing, watching out for rare but real events like anaphylactoid rash. Most adverse events recorded so far appear self-limited and resolve after brief drug withdrawal.
Future years may expand both the application and chemical diversity of liranaftate-based treatments. As global trade delivers more dermatophyte infections to temperate zones, patient populations will likely shift toward newer topicals with faster onset and fewer side effects. Molecular research into targeting other components of fungal cell membranes could inspire second-generation molecules built on liranaftate’s frame. Health systems may adopt combination products co-forming antifungals with anti-inflammatories or skin barrier restorers, aiming for greater convenience and quicker symptom control. With antimicrobial resistance on the rise, sustained investment in both liranaftate surveillance and structural refinement will remain vital to keeping superficial fungal infections in check.
Fungal infections often get dismissed as minor annoyances, but living with athlete’s foot, ringworm, or jock itch can wear down anyone’s patience. Sweat and moisture build up easily in shoes and athletic wear, creating a playground for fungi to multiply. I’ve watched friends struggle to keep their toenails healthy after workouts, sometimes sidelined by persistent itching and peeling. Most folks don’t realize just how stubborn these skin problems can be until standard drugstore powders and sprays let them down.
Liranaftate gives another option beyond the usual suspects like clotrimazole and terbinafine. Available as a topical ointment or cream, it takes direct aim at dermatophytes—the fungi behind those scaly, red rashes. This medicine is widely used in Japan and parts of Asia, and it works by blocking the growth and reproduction of fungal cells. The science points to its unique action on ergosterol synthesis, which strips fungi of their toughness and stops them in their tracks.
Athletes and folks in humid climates appreciate how quickly Liranaftate calms down itchiness and clears up redness. Studies comparing it against other treatments show better skin improvement and fewer relapses. Anyone dealing with recurring foot infections can appreciate the hope of not itching through socks year after year.
Gym showers, public pools, and sharing sports equipment all turn into hot zones for picking up a fungal bug. I remember seeing how easily toenail fungus sailed from one teammate to another in a high school locker room. We sprayed everything with disinfectant and still couldn’t outrun ringworm after a season. Washing with regular soap felt pointless until someone introduced us to stronger antifungals.
For people who care for older family members, especially those with diabetes, fungal infections are more than surface-level. Tiny cracks between the toes can turn into big health threats if left untreated. Liranaftate isn’t just a quick fix—it gives doctors another tool to reduce complications.
Over-the-counter antifungals make it easy to skip the doctor’s visit, but skipping instructions leads to wasted weeks and repeated infections. Liranaftate treatments should run full course—usually a couple of weeks—even if skin looks better after a few days. Stopping early invites a return of itching and peeling that feels like déjà vu.
Side effects tend to stay mild. People report occasional skin dryness or redness. Most reactions clear up fast and don’t stick around long. For pregnant or breastfeeding women, it’s smart to check with a health provider before use.
Self-treating fungal infections isn’t just about comfort or smooth skin. It keeps workplaces, gyms, teams, and families healthier by cutting down the spread. While Liranaftate may not have the same name recognition as other medications, it earns respect from anyone who gets stubborn athlete’s foot under control. My own experience has taught me not to underestimate how much better life feels with itch-free feet and calm, healthy skin.
Making high-quality antifungal options like Liranaftate available worldwide means fewer missed practices, less embarrassment, and better public health. Simple conversations about foot and skin hygiene in schools, sports clubs, and families go a long way. When good science meets everyday need, everyone walks away a little healthier.
Fungal skin infections like athlete’s foot, ringworm, or jock itch can drive anyone crazy. The itching, the burning, the embarrassment of red, scaly skin triggers the urge to fix the problem fast. Liranaftate cream tackles these infections well when applied with care and consistency. The biggest hurdle stems from people skipping steps or stopping early. Following the right approach matters if you want relief that sticks around for good.
Clean skin can’t be skipped. Wash your hands, clean the infected area gently with soap and water, and then pat it dry with a clean towel. Moisture trapped under the cream gives fungus another shot to grow. Skip the shortcuts, and keep towels and washcloths just for yourself to avoid spreading any infection around the house.
Squeeze out just enough cream to cover the rash in a thin, even layer. More isn’t better here—a thick glob wastes medicine and just sits on top. Use your fingertip to rub the cream gently into the skin. Allow a moment for the cream to absorb before putting clothes on, especially in skin folds or between toes. If the infection involves someone’s feet, socks should go on dry and clean.
Apply Liranaftate twice daily, morning and night, exactly as the package or your doctor says. Even after symptoms begin to fade, stick with treatment for the recommended time—usually between two and four weeks, depending on the infection. Prematurely stopping can lead to quick relapses, and the itch winds up worse later on. The medicine needs time to clear any lingering fungus that eyes can’t see.
Skipping doses and sharing creams stand out as leading reasons fungal rashes linger or worsen. The fungus that causes things like tinea pedis and ringworm lives on towels, shoes, and floors. If the cream works but someone keeps picking up spores from the environment, the cycle drags on. It’s smart to wash socks, underwear, towels, and bedsheets in hot water at least weekly during treatment. Dermatologists also point out that airing out affected areas helps—fungal infections grow best in warm, damp, closed-up spots.
Liranaftate works by disrupting the way certain fungi build their cell walls. Studies show it’s as effective as other over-the-counter antifungals, if not a bit faster at clearing up some types of athlete’s foot. Researchers have found that using the cream as directed gives noticeable improvement within a week for most people. Still, a full cure depends on applying it for the whole cycle. Resistant strains aren’t the norm, but skipping applications or stopping too early can give stubborn fungus a reason to hang around.
Take the medicine with you if you’ll need to apply it during the day. If redness, swelling, or pain gets worse, or if the rash spreads or looks infected, don’t tough it out—a healthcare professional should check for bacterial infection or other problems. Don’t use more than instructed or try to mix different antifungal creams without talking to a pharmacist or doctor. Sticking to one proven method gives the best odds of knocking out the issue.
Living through a stubborn itch or rash provides a quick lesson in sticking to daily routines. Liranaftate cream, used well, does the heavy lifting. Hands washed, skin dry, apply as directed, finish the course, keep things clean, and the chances for clear skin grow a lot better every day.
Liranaftate appears on pharmacy shelves all over Asia as an over-the-counter treatment for athlete’s foot and other fungal rashes. Folks trust its fast action and the way it sticks around on the skin. Dermatologists often suggest it for tough cases where more common creams just don’t seem to clear the problem. Still, like any remedy you smear on your skin, it’s smart to know what might happen beyond just clearing up that itchy patch.
Anyone who has battled athlete’s foot understands how desperate a person becomes for some relief. In my case, drugstore brands barely made a dent. Liranaftate, recommended by a local doctor, dried the rash up within a week. I only noticed a bit more dry skin in the area. That surprised me, so I did what most people do—I read the packaging. According to the leaflet and local pharmacy, side effects don’t stack up too long, but they’re still worth knowing.
In Japan and China, where Liranaftate gets prescribed often, reported side effects land mostly on mild and local. Itching, a little redness, or dry skin pop up sometimes. Some patients claim a burning feeling after putting on the cream, although that usually disappears quickly. Blisters or swelling seem rare, but there are case reports.
Data from post-marketing surveillance highlights that less than one out of a hundred people notice serious problems from Liranaftate. This mirrors what skin specialists see in clinics, according to studies in the Journal of Dermatology and updated reviews published by health agencies. Severe allergic reactions don’t usually trace back to this medicine. Still, contact dermatitis can develop if someone reacts to an extra ingredient in the cream or spray.
Some folks run a higher chance of side effects. Anyone with sensitive skin or a known allergy to antifungal agents wants to test a small spot before using a large amount. Children and the elderly often feel the sting of new medicines sooner, so extra care applies there. If broken skin or raw wounds are present, Liranaftate can irritate the area and sometimes delay healing.
There’s plenty of ways to cut down on unwanted reactions. Start with clean, dry skin before applying a thin layer. Don’t rub in several times a day unless a doctor suggests it. Avoid mixing with other strong creams, especially anything containing steroids or exfoliating acids. If problems like swelling, blisters, or open sores show up, set the tube aside and check in with a pharmacist or dermatologist.
Doctors and pharmacists keep up with the latest research because new medicines and rare responses turn up every year. Some clinics share pamphlets about side effects in easy language. The Japanese regulatory authority, the Pharmaceuticals and Medical Devices Agency, posts updated lists of possible reactions and offers a hotline for people who run into trouble after using an over-the-counter cream like Liranaftate.
People deserve clear and accurate advice, not sales talk. It pays to ask questions and do a quick self-check before starting a new skin treatment. If side effects are mild, some patience and moisturizing resolve them quickly. Serious problems are rare but not impossible, making honest conversations with health professionals more important than ever.
Fungal infections come in all shapes and sizes, from the athlete’s foot plaguing gym-goers to difficult nail infections that stick around for ages. Liranaftate pops up on pharmacy shelves as a go-to for some skin fungal problems, promising a solution for those tired of flakes, redness, and itching. Growing up in a humid city where fungi seemed to thrive all summer, I remember the local buzz around “newer” creams like this one. People hoped it could clear any patch or rash. The reality, though, comes with a dose of science and clear limitations.
Pharmacists praise liranaftate for its role against dermatophytes—think tinea pedis (athlete's foot), tinea cruris (jock itch), and tinea corporis (ringworm). Here, it acts by stopping the growth of fungus on the surface of the skin. Studies, mostly from East Asia, report strong results with once-daily use. I’ve seen neighbors clear up angry, inflamed toes in just a few weeks by sticking with a routine. It performs especially well for those who can’t tolerate steroids or have sensitive skin.
Not every fungus bows down to liranaftate. Yeasts like Candida, the culprit behind diaper rash and oral thrush, scoff at it. Fungal nail infections (onychomycosis) hide deep under nails where topical agents struggle to reach. Here, liranaftate's benefits drop off sharply. I’ve watched people spend months chasing stubborn nail discoloration, hopeful that over-the-counter creams could sidestep a doctor visit or oral medication. Their frustration grows when nothing improves. Researchers agree: lab data and real-life experience both point to the same thing—liranaftate shines for superficial skin infections, not tough, deep-seated or yeast-driven issues.
Belief in a single “miracle cream” leads to lost time, money, and sometimes a spreading infection. Local clinics report cases where children’s mild ringworm morphs into angry, widespread patches after weeks of ineffective home treatment. People with weakened immune systems, like the elderly and those with diabetes, pay the steepest price. Delayed care gives fungi an advantage. It’s not just about itching or embarrassment—untreated fungal infections raise the risk of secondary bacterial infections that can land someone in the hospital.
Trust in medicine depends on clear instructions and tough conversations about limits. Liranaftate does the job when used as intended, but doctors and pharmacists should call out where it falls flat. Pharmacies play a frontline role; a helpful pharmacist can steer someone away from an inappropriate cream and toward a check-up if things look suspicious or the rash resists care. Patients need real facts, not hope packaged in glossy marketing.
Getting the right treatment starts with knowing what lies beneath. Simple skin scrapings, available in many clinics, quickly identify the fungus at fault. Picking a cream like liranaftate becomes an informed choice. For nail infections, yeast, or any infection sticking around despite good hygiene, doctors often recommend oral prescription medications. The right prescription at the right time can cut frustration and help people get back to comfort and confidence. Keeping up with all the new options, like liranaftate, stays important—but matching them to the real problem makes all the difference.
Liranaftate sits on pharmacy shelves as a topical antifungal cream. It targets athlete’s foot, ringworm, and similar skin issues. In Japan and parts of Asia, doctors reach for this medicine more often than in Western clinics. Those little tubes promise relief from itching and rashes, but questions keep appearing around who should actually use them—especially parents and expectant mothers.
Parents often look for something to bring quick relief to their children’s skin troubles. Anyone with a toddler knows how fast heat and humidity can bring on fungal rashes. Liranaftate works on the fungus directly, so it can shorten the misery when applied as directed. But kids have thinner, more sensitive skin, and that means creams get absorbed faster and enter the bloodstream more easily than with adults. Most large clinical trials for Liranaftate didn’t include young children. The published studies focus on adults, and pediatric safety data is thin. Japanese guidelines advise that a doctor should supervise use in children under 7, mentioning the possibility of increased side effects. In my experience, some parents try over-the-counter antifungal creams before seeing a pediatrician, thinking these are always safe because they’re sold without a prescription. Some kids end up with skin irritation, and a rare few see their rash worsen. This highlights the need for guidance—especially since kids scratch and rub creams everywhere.
Pregnant women fight itchy, sweaty feet and can’t always avoid communal showers or gym floors. Fungal infections are common, and treatment feels urgent, but every medication choice takes on extra weight. With Liranaftate, product inserts label safety during pregnancy as “uncertain.” Published animal studies show no fertility or developmental issues at normal doses, though high doses led to problems in rats. Human data is harder to come by. European and US guidelines stick with clotrimazole and terbinafine creams since those have long-term safety records and more research behind them. In places where Liranaftate is commonly recommended, doctors lean on their clinical experience over published human safety evidence.
Doctors juggle many factors before reaching for a prescription. For children with itchy red feet, alternatives exist with robust safety profiles—clotrimazole, miconazole, and terbinafine among them. These have well-documented clinical histories for younger patients. For pregnant women, most dermatologists suggest non-pharmaceutical measures in mild cases: keep the skin dry, wash with gentle soap, and avoid public showers. If medications are needed, they choose creams with the most published safety evidence.
Some parents and expectant mothers land in a tricky spot. Pharmacies sometimes push sales of creams to worried people without adequate advice. Safety depends not just on chemistry, but on how well healthcare providers communicate and guide use for vulnerable groups. Doctors giving clear, personalized advice—especially for the little ones and those expecting—make all the difference between relief and regret.
Medical guidelines and product researchers could run targeted studies on Liranaftate’s use in kids and during pregnancy, instead of relying on animal data or general caution. Regulators and manufacturers ought to make warnings and precautions visible on packaging, not hidden in fine print. Pharmacists should step in more often, pressing pause and asking who the cream is for before ringing up a sale.
Whenever doubt lingers, reaching out to a healthcare professional matters most. A short conversation often saves parents and mothers months of stress down the road. Tough as it is to sit with uncertainty, sometimes holding off and asking for help is the choice that protects those who rely on us most.
| Names | |
| Preferred IUPAC name | O-(2-cyano-3-ethoxy-3-oxopropyl) N-(5,6,7,8-tetrahydronaphthalen-2-yl)carbamothioate |
| Other names |
Zefnart Lofena Liranaffin Liranafin |
| Pronunciation | /lɪˈrɑː.næf.teɪt/ |
| Identifiers | |
| CAS Number | 88678-31-3 |
| 3D model (JSmol) | `3D model (JSmol) string for Liranaftate:` `CCCOC(=O)COC(=O)/C=C/c1ccc(SC(=O)Nc2nccs2)cc1` |
| Beilstein Reference | 3440132 |
| ChEBI | CHEBI:77967 |
| ChEMBL | CHEMBL2104387 |
| ChemSpider | 60852 |
| DrugBank | DB11666 |
| ECHA InfoCard | 1007001 |
| EC Number | EC 620-864-7 |
| Gmelin Reference | 919973 |
| KEGG | D08174 |
| MeSH | D000073640 |
| PubChem CID | 65902 |
| RTECS number | OZ0082000 |
| UNII | H5F85FE9TV |
| UN number | UN3077 |
| Properties | |
| Chemical formula | C18H17NOS2 |
| Molar mass | 355.47 g/mol |
| Appearance | White crystalline powder |
| Odor | Odorless |
| Density | 1.26 g/cm³ |
| Solubility in water | Insoluble in water |
| log P | 2.74 |
| Acidity (pKa) | 13.61 |
| Basicity (pKb) | 11.61 |
| Magnetic susceptibility (χ) | -7.9e-6 |
| Refractive index (nD) | 1.585 |
| Viscosity | Viscosity: Not less than 15 mPa·s |
| Dipole moment | 2.92 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | Std molar entropy (S⦵298) of Liranaftate is 547.6 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -619.1 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -8599 kJ/mol |
| Pharmacology | |
| ATC code | D01AE25 |
| Hazards | |
| Main hazards | May cause skin irritation. |
| GHS labelling | GHS labelling string for Liranaftate: **"GHS07, Warning, H315, H319, P264, P280, P305+P351+P338, P337+P313"** |
| Pictograms | GHS07 |
| Signal word | Warning |
| Hazard statements | H315: Causes skin irritation. H319: Causes serious eye irritation. |
| Precautionary statements | IF ON SKIN: Wash with plenty of soap and water. If skin irritation or rash occurs: Get medical advice/attention. Take off contaminated clothing and wash before reuse. |
| Flash point | > 120°C |
| Lethal dose or concentration | LD₅₀ oral (rat): >2000 mg/kg |
| LD50 (median dose) | LD50 (median dose): >2,000 mg/kg (rat, oral) |
| PEL (Permissible) | Not established |
| REL (Recommended) | Topical: 2% cream/solution once daily for 2-4 weeks |
| IDLH (Immediate danger) | Not listed |
| Related compounds | |
| Related compounds |
Tolnaftate Terbinafine Naftifine |
